Current perspectives in HIV post-exposure prophylaxis
Authors:
Open Access
- 1 October 2014
- journal article
- review article
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. 6, 147-158
Abstract
The incidence of human immunodeficiency virus (HIV) infection continues to rise among core groups and efforts to reduce the numbers of new infections are being redoubled. Post-exposure prophylaxis (PEP) is the use of short-term antiretroviral therapy (ART) to reduce the risk of acquisition of HIV infection following exposure. Current guidelines recommend a 28-day course of ART within 36–72 hours of exposure to HIV. As long as individuals continue to be exposed to HIV there will be a role for PEP in the foreseeable future. Nonoccupational PEP, the vast majority of which is for sexual exposure (PEPSE), has a significant role to play in HIV prevention efforts. Awareness of PEP and its availability for both clinicians and those who are eligible to receive it are crucial to ensure that PEP is used to its full potential in any HIV prevention strategy. In this review, we provide current evidence for the use of PEPSE, assessment of the risk of HIV transmission, indications for PEP, drug regimens, and management of patients started on PEP. We summarize national and international guidelines for the use of PEPSE. We explore the place of PEP within the wider strategy of reducing HIV incidence rates in the era of treatment as prevention and pre-exposure prophylaxis. We also consider the implications of recent data from interventional and observational studies demonstrating significant reductions in the risk of HIV transmission within a serodiscordant relationship if the HIV-positive partner is taking effective ART upon PEP guidelines.Keywords
This publication has 77 references indexed in Scilit:
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)HIV Medicine, 2013
- Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/LamivudineAntiviral Therapy, 2012
- Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in womenThe Lancet, 2011
- Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)Antimicrobial Agents and Chemotherapy, 2011
- Use of Non-Occupational Post-Exposure Prophylaxis does not Lead to an Increase in High Risk Sex Behaviors in Men Who have Sex with Men Participating in the EXPLORE TrialAIDS and Behavior, 2010
- Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidanceSexually Transmitted Infections, 2006
- Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviorAIDS, 2004
- Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1The Lancet, 2001
- Per-Contact Risk of Human Immunodificiency Virus Tramnsmision between Male Sexual PartnersAmerican Journal of Epidemiology, 1999
- Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to InfantNew England Journal of Medicine, 1996